Skip to Main Content
  • Search by ticker
  • Sign up for emails
  • Contact Us
  • 866-476-7523
Leveraged & Inverse ETFs

PILL

The Direxion Daily Pharmaceutical & Medical Bull 3X Shares seek daily investment results, before fees and expenses, of 300% of the performance of the S&P Pharmaceuticals Select Industry Index. There is no guarantee the fund will meet its stated investment objective.

NAVas of Jun 08, 2023
1 Day NAV Changeas of Jun 08, 2023
$8.24
$0.01(0.12 %)

Related Links

Overview

Fund Information

Fund SymbolDaily TargetIntra-day ValueBenchmark IndexSecurity IdentifierExpense Ratio (gross/net %)Inception Date
PILL300%PILL.IVSPSIPHTR25460E6461.13 / 1.00*Nov 15, 2017

This leveraged ETF seeks a return that is 300% the return of its benchmark index for a single day. The fund should not be expected to provide three times the return of the benchmark’s cumulative return for periods greater than a day.

Documents & Downloads

Strategy & Benefits

You know that TRADING is different than investing. But the opportunity to take advantage of short-term trends is only won, if you get the direction right.

Whether you’re a bull or a bear, Direxion is with you. Our leveraged ETFs are powerful tools built to help you:

  • Magnify your short-term perspective with daily 3X leverage
  • Go where there’s opportunity, with bull and bear funds for both sides of the trade; and
  • Stay agile – with liquidity to trade through rapidly changing markets

Leveraged and inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments.


Target Index

The S&P Pharmaceuticals Select Industry Index (SPSIPHTR) is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the Global Industry Classification Standard (GICS) pharmaceuticals subindustry. One cannot directly invest in an index.


Pricing & Performance

NAV and Market Price information as of June 08, 2023. Line chart shows pricing trend over the last 30 days.

Net asset value (NAV)
  • 8.24
    NAV $
  • 0.01
    Change $
  • 0.12
    Change %
Market price closing
  • 8.23
    Market $
  • 0.02
    Change $
  • 0.24
    Change %
Premium / Discount
-0.01
monthly1M %3M %YTD %1Y %3Y %5Y %10Y %Since InceptionInception DateExpense Ratio*
(Gross / Net %)
NAV-18.67 -16.75 -17.77 -32.38 -22.31 -21.92 -19.49 11/15/20171.13 / 1.00*
Market Close-18.30 -15.79 -17.20 -32.03 -22.15 -21.82 -19.39
As of May 31, 2023
quarterly1M %3M %YTD %1Y %3Y %5Y %10Y %Since InceptionInception DateExpense Ratio*
(Gross / Net %)
NAV-3.40 -4.58 -4.58 -40.27 -4.18 -18.04 -17.79 11/15/20171.13 / 1.00*
Market Close-2.72 -4.35 -4.35 -40.40 -4.39 -18.03 -17.75
SPSIPHTR-0.23 0.42 0.42 -8.39 5.44 0.53 0.86 -
As of March 31, 2023
The Primary Listing Exchange is the NYSE Arca, Inc.

* The Net Expense Ratio includes management fees, other operating expenses and Acquired Fund Fees and Expenses. If Acquired Fund Fees and Expenses were excluded, the Net Expense Ratio would be 0.95%. The Fund’s adviser, Rafferty Asset Management, LLC (“Rafferty”) has entered into an Operating Expense Limitation Agreement with the Fund. Under the Operating Expense Limitation Agreement, Rafferty has contractually agreed to waive all or a portion of its management fee and/or reimburse the Fund for Other Expenses through September 1, 2024, to the extent that the Fund’s Total Annual Fund Operating Expenses exceed 0.95% of the Fund’s average daily net assets (excluding, as applicable, among other expenses, taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions and extraordinary expenses). If these expenses were included, the expense ratio would be higher.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate. An investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. Returns for performance under one year are cumulative, not annualized.

Short-term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. For additional information, see the fund’s prospectus.


Distributions

Record DateEx DatePay DateIncome DividendShort-Term Capital GainLong-Term Capital Gain
03/22/202303/21/2023 03/28/2023 0.01911
12/21/202212/20/2022 12/28/2022 0.03171
09/21/202209/20/2022 09/27/2022 0.01673
06/23/202206/22/2022 06/29/2022 0.00361
03/23/202203/22/2022 03/29/2022 0.00817
12/22/202112/21/2021 12/29/2021 0.00007

Tax Documents

Download the following Tax Reporting Documents